- Global Pharma News & Resources

Pyramidion Technology Group, Inc. (OTC: PYTG) Appoints New Scientific Advisory Board Team to Support Company Strategy in the Medical CBD Industry

WESTON, Florida, August 30, 2018 /PRNewswire/ --

Pyramidion Technology Group, Inc. (or the "Company") (OTC: PYTG), today announced the appointment of a New Advisory Medical Board to lead the new direction of the company in the Medical Alternative Medicine and Natural Nutraceutical Products. The new Medical Board will bring an immense, collective and unique set of experiences in the Medical CBD affairs, unmatched leadership and guidance to help drive Pyramidion towards its strategic mission.

Mark Sabbota 

Dr. Mark Sabbota is board-certified in cardiology and internal medicine. He earned his medical degree from Chicago College of Osteopathic Medicine in 1995. Dr. Sabbota completed his residencies at Botsford General Hospital in 1998 and 2001 and his fellowship at University of Michigan Medical Center in 2001.

On the appointment, CEO Carlos Hurtado, said, "Pyramidion has a mission to make CBD available to any patient who can benefit from safe and reliable sources. The addition of these Reputed Physicians to our Medical Board will lead to even greater access for patients to the best CBD Products in the Market and built a solid Doctors-Patient Relationship and changing their life for better health. 

About Pyramidion Technology Group, Inc.

Pyramidion Technology Group, Inc. ("PYTG" or the "Company") is best described as a business incubator. The purpose of our business model is to leverage equity, to acquire, merge and or joint venture with early stage companies in emerging sectors, to facilitate growth and cash flow utilizing a diverse distribution method.

Our intention is to develop and acquire fast growing companies in up-trending industries and positioning technology for economic growth. This platform will combine natural relationships, marketing synergies and distribution methods that enable combined companies to provide a wide variety of unique and complete solutions, services and necessities to consumers. We believe our overall business model could effectively create a company of unlimited opportunities for our growing shareholder base.

For more information on PYTG, please visit the Company's website at

To be added to the Company investor email list, please email with PYTG in the subject line.


This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance

on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at




Phone: +1-954-651-6816

Editor Details

Last Updated: 31-Aug-2018